We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pharma Questions Impurity Thresholds in Topical Ophthalmic Drug Guidance
Pharma Questions Impurity Thresholds in Topical Ophthalmic Drug Guidance
Novartis and Lupin are seeking additional clarity on thresholds of unspecified impurities in topical ophthalmic drug products, according to comments on the FDA’s October draft guidance on the subject.